var data={"title":"Postoperative nausea and vomiting","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Postoperative nausea and vomiting</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/contributors\" class=\"contributor contributor_credentials\">Jessica Feinleib, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/contributors\" class=\"contributor contributor_credentials\">Lori H Kwan, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/contributors\" class=\"contributor contributor_credentials\">Ammar Yamani, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/contributors\" class=\"contributor contributor_credentials\">Natalie F Holt, MD, MPH</a></dd><dd><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/contributors\" class=\"contributor contributor_credentials\">Andrew Davidson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/contributors\" class=\"contributor contributor_credentials\">Marianna Crowley, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 09, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H959820015\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nausea, vomiting, and retching frequently complicate recovery from anesthesia. Postoperative nausea and vomiting (PONV) is a patient-important outcome; patients often rate PONV as worse than postoperative pain [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/1\" class=\"abstract_t\">1</a>]. PONV usually resolves or is treated without sequelae, but may require unanticipated hospital admission and delay recovery room discharge [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/2,3\" class=\"abstract_t\">2,3</a>]. In addition, vomiting or retching can result in wound dehiscence, esophageal rupture, aspiration, dehydration, increased intracranial pressure, and pneumothorax.</p><p>The term PONV is typically used to describe nausea <span class=\"nowrap\">and/or</span> vomiting or retching in the postanesthesia care unit (PACU) and in the immediate 24 postoperative hours. Postdischarge nausea and vomiting (PDNV) refers to symptoms that occur after discharge for outpatient procedures. Postoperative vomiting (POV) is usually measured and discussed in children, rather than PONV, because nausea may be difficult to assess in young children.</p><p>This topic will discuss the risk factors for PONV, preventive strategies, and treatment of PONV in adults and children. Pathophysiology of nausea and vomiting is discussed separately. (See <a href=\"topic.htm?path=approach-to-the-adult-with-nausea-and-vomiting#H2\" class=\"medical medical_review\">&quot;Approach to the adult with nausea and vomiting&quot;, section on 'Pathophysiology'</a>.)</p><p class=\"headingAnchor\" id=\"H2239430484\"><span class=\"h1\">PATHOPHYSIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nausea and vomiting may be induced through a variety of central and peripheral mechanisms. (See <a href=\"topic.htm?path=approach-to-the-adult-with-nausea-and-vomiting#H2\" class=\"medical medical_review\">&quot;Approach to the adult with nausea and vomiting&quot;, section on 'Pathophysiology'</a>.)</p><p>Five principle neurotransmitter receptors mediate nausea and vomiting: muscarinic M1, dopamine D2, histamine H1<sub> </sub>5-hydroxytryptamine (HT)-3 serotonin, and neurokinin 1 (NK1) &ndash; substance P [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/4\" class=\"abstract_t\">4</a>]. All of these receptors may be targets for prevention or treatment of PONV. The pathophysiologic pathways for PONV are shown in a figure (<a href=\"image.htm?imageKey=ANEST%2F110527\" class=\"graphic graphic_figure graphicRef110527 \">figure 1</a>). (See <a href=\"#H144014180\" class=\"local\">'Antiemetics'</a> below.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Central mechanisms</strong> &ndash; Nausea and emesis can be triggered by higher cortical centers communicating with the central pattern generator (formerly called the vomiting center) in the medulla. In the perioperative period, fear, pain, anxiety, conditioned nausea related to environmental cues, and stimulation of the vestibular system are central stimuli that may cause nausea and vomiting. As an example, during tympanoplasty, surgical stimulation of the vestibular system, transmitted via the H<sub>1</sub> histamine and M<sub>1</sub> acetylcholine receptors, may result in profound PONV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/5\" class=\"abstract_t\">5</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Peripheral mechanisms </strong>&ndash;<strong> </strong>Direct gastric stimulation from gastric trauma, blood, or toxins induces release of substance P and serotonin from enterochromaffin cells, thereby activating the vagal and splanchnic nerve 5-HT<sub>3</sub> receptors [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/6\" class=\"abstract_t\">6</a>]. Vagal and splanchnic nerve afferents terminate in the nucleus tractus solitarius in the brain stem, near or within the area postrema (also called the chemoreceptor trigger zone). Bowel surgery and blood in the gastrointestinal tract from oral or ear, nose, and throat surgery may cause nausea and vomiting via this pathway, though the mechanisms by which serotonergic stimuli cause nausea and vomiting are incompletely understood.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Drugs and toxins </strong>&ndash;<strong> </strong>The molecular and neural mechanisms by which drugs and toxins, including anesthetics and opioids, cause nausea and vomiting are complex and incompletely understood [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/7\" class=\"abstract_t\">7</a>]. Both opioids and inhalation anesthetics may cause nausea and vomiting by stimulation of the area postrema at the base of the fourth ventricle in the medulla. The area postrema then communicates with the central pattern generator via dopamine and serotonin to trigger the vomiting reflex [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/8,9\" class=\"abstract_t\">8,9</a>].</p><p/><p class=\"headingAnchor\" id=\"H712007825\"><span class=\"h1\">RISK FACTORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Without prophylaxis, PONV occurs in approximately 30 percent of children and adults after anesthesia [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/10-13\" class=\"abstract_t\">10-13</a>]. The risk of PONV for an individual patient varies widely; the rate of PONV may be as high as 80 percent in high-risk patients [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/11\" class=\"abstract_t\">11</a>].</p><p>The incidence of PONV varies with patient factors, anesthetic choices, and possibly the type of surgery.</p><p class=\"headingAnchor\" id=\"H3592868051\"><span class=\"h2\">Patient risk factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patient characteristics that increase the risk of PONV include the following, in decreasing order of risk:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Preoperative nausea and vomiting</strong> &ndash; The most evident, but often overlooked, factor is nausea and vomiting prior to the anesthetic (eg, patients with renal colic).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Female gender </strong>&ndash;<strong> </strong>Female gender is the most reliable patient-specific predictor for PONV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/14,15\" class=\"abstract_t\">14,15</a>]. A meta-analysis of 22 prospective studies including over 95,000 adults found that female gender was the strongest overall predictor for PONV (odds ratio [OR] 2.57) [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/14\" class=\"abstract_t\">14</a>].</p><p/><p class=\"bulletIndent1\">In children, prior to puberty, female gender does not increase the risk of PONV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/16-18\" class=\"abstract_t\">16-18</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>History of PONV or motion sickness </strong>&ndash;<strong> </strong>Prior PONV <span class=\"nowrap\">and/or</span> motion sickness increase the risk of PONV in adults (OR 2.09) [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/12,14,15,19\" class=\"abstract_t\">12,14,15,19</a>].</p><p/><p class=\"bulletIndent1\">In children, both a prior history of PONV or postoperative vomiting (POV) and a history of PONV or POV in a parent or sibling increase the risk of <span class=\"nowrap\">POV/PONV</span> [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/13\" class=\"abstract_t\">13</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Nonsmoking </strong>&ndash;<strong> </strong>Nonsmoking status is an independent risk factor for PONV (OR 1.82) [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/12,14,15,20\" class=\"abstract_t\">12,14,15,20</a>].</p><p/><p class=\"bulletIndent1\">Smoking status does not usually apply to children, and the risk of <span class=\"nowrap\">POV/PONV</span> in children exposed to secondhand smoke has not been studied.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Age </strong>&ndash;<strong> </strong>Most studies have reported a slight, progressive decrease in PONV in adults with increasing age [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/10,14,21\" class=\"abstract_t\">10,14,21</a>]. A prospective study including approximately 2200 patients who underwent general anesthesia reported that age &lt;50 was a risk factor for PONV in the postanesthesia care unit (PACU) (OR 1.79) and postdischarge nausea and vomiting (PDNV) (OR 2.17) [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/21\" class=\"abstract_t\">21</a>].</p><p/><p class=\"bulletIndent1\">In children, young age appears to be protective. POV rarely occurs in children &lt;3 years of age, and increases in frequency with age &gt;3, decreasing again with puberty [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/16\" class=\"abstract_t\">16</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Chemotherapy-induced nausea and vomiting </strong>&ndash; A history of chemotherapy-induced nausea and vomiting (CINV) may increase the risk of PONV (OR 3.15) [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/22\" class=\"abstract_t\">22</a>]. (See <a href=\"topic.htm?path=pathophysiology-and-prediction-of-chemotherapy-induced-nausea-and-vomiting\" class=\"medical medical_review\">&quot;Pathophysiology and prediction of chemotherapy-induced nausea and vomiting&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2162413264\"><span class=\"h2\">Anesthetic factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of anesthetic factors have been associated with PONV, some of which may be modified to reduce risk.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Anesthetic technique </strong>&ndash;<strong> </strong>General anesthesia is associated with a higher incidence of PONV compared with purely regional anesthesia [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/12\" class=\"abstract_t\">12</a>]. Regional anesthesia, in both adults and children, may reduce PONV by reducing opioid administration for postoperative pain.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Volatile anesthetics </strong>&ndash;<strong> </strong>The use of volatile anesthetics is an important risk factor for PONV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/12,23-25\" class=\"abstract_t\">12,23-25</a>]. In a study of 1180 surgical patients, those randomly assigned to receive potent inhalation anesthesia with <a href=\"topic.htm?path=isoflurane-drug-information\" class=\"drug drug_general\">isoflurane</a>, enflurane, or <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a> had a higher risk of PONV compared with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> (OR 2.4, 2.3, and 2.3, respectively) [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/23\" class=\"abstract_t\">23</a>]. The degree of risk was similar for each of the volatile anesthetics, was dose-related (ie, based on the duration of anesthesia), and was limited to the early postoperative period.</p><p/><p class=\"bulletIndent1\">Another meta-analysis of 57 trials in adults and 13 trials in children found that <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> anesthesia resulted in 3.5-fold reduction of PONV in adults and 5.7-fold reduction in children [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/26\" class=\"abstract_t\">26</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Intravenous (IV) anesthetics </strong>&ndash;<strong> </strong><a href=\"topic.htm?path=ketamine-drug-information\" class=\"drug drug_general\">Ketamine</a> and <a href=\"topic.htm?path=etomidate-drug-information\" class=\"drug drug_general\">etomidate</a> do not independently increase PONV at doses commonly administered for induction of anesthesia [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/27\" class=\"abstract_t\">27</a>].<strong> </strong>Low-dose ketamine may reduce PONV by decreasing postoperative opioid requirements [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/28\" class=\"abstract_t\">28</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=nitrous-oxide-drug-information\" class=\"drug drug_general\">Nitrous oxide</a><strong> (N</strong><strong><sub>2</sub></strong><strong>O) </strong>&ndash;<strong> </strong>N<sub>2</sub>O may modestly increase the risk of PONV, especially in high-risk adults and children, compared with N<sub>2</sub>O-free anesthesia [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/25\" class=\"abstract_t\">25</a>]. Studies of the emetogenic effect of N<sub>2</sub>O have been conflicting, with some reporting an increase in PONV with N<sub>2</sub>O [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/29-31\" class=\"abstract_t\">29-31</a>], and others reporting no effect [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/32-34\" class=\"abstract_t\">32-34</a>]. A meta-analysis of 30 studies including approximately 4600 patients reported a modestly higher incidence of PONV with N<sub>2</sub>O compared with N<sub>2</sub>O-free anesthesia (33 versus 27 percent) [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/24\" class=\"abstract_t\">24</a>]. The maximal risk reduction with avoidance of N<sub>2</sub>O was in women (OR 0.7), and the difference between groups was eliminated by administration of a <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> infusion.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Duration of anesthesia</strong> &ndash; Longer duration of anesthesia with volatile anesthetics may increase the risk of PONV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/14,15,35,36\" class=\"abstract_t\">14,15,35,36</a>]. In addition to the increase in dose of anesthetics, longer procedures tend to be more invasive, and tend to require administration of larger doses of postoperative opioids than shorter procedures.</p><p/><p class=\"bulletIndent1\">In children, surgery &gt;30 minutes increases the risk of POV compared with shorter procedures [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/16\" class=\"abstract_t\">16</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Opioid administration </strong>&ndash;<strong> </strong>Multiple studies have shown that administration of postoperative opioids increases the incidence of PONV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/11,12,14\" class=\"abstract_t\">11,12,14</a>] in a dose-related manner [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/37\" class=\"abstract_t\">37</a>]. Multimodal postoperative pain control strategies that reduce opioid administration should reduce the incidence of PONV. In children, administration of <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a> may be particularly beneficial for its opioid-sparing effects and to reduce the incidence of emergence delirium. (See <a href=\"topic.htm?path=management-of-acute-perioperative-pain#H447933291\" class=\"medical medical_review\">&quot;Management of acute perioperative pain&quot;, section on 'Strategy for perioperative pain control'</a> and <a href=\"topic.htm?path=emergence-delirium-and-agitation-in-children#H3361151633\" class=\"medical medical_review\">&quot;Emergence delirium and agitation in children&quot;, section on 'Prevention'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=neostigmine-drug-information\" class=\"drug drug_general\">Neostigmine</a><strong> &mdash; </strong>Contrary to popular belief, IV neostigmine for reversal of neuromuscular block does not appear to significantly increase the risk of PONV. A meta-analysis of 10 randomized trials including 933 patients reported that the combination of neostigmine with either <a href=\"topic.htm?path=atropine-drug-information\" class=\"drug drug_general\">atropine</a> or <a href=\"topic.htm?path=glycopyrrolate-glycopyrronium-drug-information\" class=\"drug drug_general\">glycopyrrolate</a> did not significantly increase the incidence of overall nausea (relative risk [RR] 1.24) or vomiting (RR 0.91) [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/38\" class=\"abstract_t\">38</a>].</p><p/><p class=\"headingAnchor\" id=\"H2012868701\"><span class=\"h2\">Type of surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Studies of the effect of the type of surgery on the incidence of PONV have reported conflicting results. The best evidence suggests that cholecystectomy, gynecologic, and laparoscopic procedures are associated with modestly increased risk of PONV compared with other general surgical procedures [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/14\" class=\"abstract_t\">14</a>].</p><p>In children, strabismus surgery is an independent, and possibly the most significant, predictor for POV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/13,16,39\" class=\"abstract_t\">13,16,39</a>]. In addition, POV occurs in as many as 70 percent of children without prophylaxis who undergo adenotonsillectomy [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/40\" class=\"abstract_t\">40</a>] and 40 percent of those who undergo inguinal scrotal or penile procedures [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/41\" class=\"abstract_t\">41</a>].</p><p class=\"headingAnchor\" id=\"H435405590\"><span class=\"h2\">Risk scores</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of predictive models, or scoring systems, have been developed to stratify the risk of PONV, based on patient, anesthetic, and surgical risk factors. The score may be used to determine the appropriate degree of intervention for prophylaxis (<a href=\"image.htm?imageKey=ANEST%2F86808\" class=\"graphic graphic_figure graphicRef86808 \">figure 2</a>).</p><p class=\"headingAnchor\" id=\"H440882333\"><span class=\"h3\">Risk score for postoperative nausea and vomiting for adults</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We use the simplified risk score for PONV that was created by Apfel, et al. [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/11\" class=\"abstract_t\">11</a>] to evaluate adults preoperatively, and base the preventive strategy on the resulting degree of predicted risk. The simplified risk score is easy to use and accurately predicts the risk for PONV in our adult patients. The components of the simplified risk score include the following four highly predictive risk factors:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Female gender</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nonsmoker</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>History of motion sickness or previous PONV</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Expected administration of postoperative opioids</p><p/><p>This risk score has been validated within and across institutions; the presence of 0, 1, 2, 3, and 4 of these risk factors corresponds to risk of PONV of 10, 20, 40, 60, and 80 percent, respectively [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/11\" class=\"abstract_t\">11</a>].</p><p class=\"headingAnchor\" id=\"H2088878686\"><span class=\"h3\">Risk score for postoperative vomiting for children</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The risk scores used for adult patients are not applicable for children [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/17\" class=\"abstract_t\">17</a>]. An alternative scoring system for children, called the Eberhart classification, includes the following risk factors [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/16\" class=\"abstract_t\">16</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Age &gt;3 years</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Duration of surgery &gt;30 minutes</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Strabismus surgery</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>History of POV or a relative with <span class=\"nowrap\">POV/PONV</span></p><p/><p>The risk of POV for children with 0 to 1, 2, 3, or 4 of these risk factors is associated with an incidence of PONV of 10, 30, 50, and 70 percent, respectively. This scoring system has also been validated for children having surgery other than strabismus surgery; POV was observed in 3, 11, 30, and 40 percent for children who had 0, 1, 2 or 3 risk factors, respectively [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/13\" class=\"abstract_t\">13</a>].</p><p class=\"headingAnchor\" id=\"H1226576483\"><span class=\"h1\">PREVENTION</span></p><p class=\"headingAnchor\" id=\"H2659650314\"><span class=\"h2\">Our strategy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The management strategy for PONV should include risk assessment, multimodal preventive measures based on the individual patient's risk, and evidenced-based interventions when PONV occurs.</p><p class=\"headingAnchor\" id=\"H620505717\"><span class=\"h3\">Preventive measures for all patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We employ a multimodal, opioid-sparing strategy for effective postoperative pain control; the reduction of pain has been correlated with a reduction in PONV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/42\" class=\"abstract_t\">42</a>]. Additional preventive measures may include modification of anesthetic technique and medications used, administration of antiemetics, and use of nonpharmacologic measures for prophylaxis.</p><p class=\"headingAnchor\" id=\"H1157266081\"><span class=\"h3\">Risk stratification</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The decision to administer prophylaxis for PONV should be made with the following factors in mind:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The patient-specific risk of PONV, rated as low, medium, or high</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The consequences of nausea and vomiting related to the surgical procedure (eg, wound disruption, increase in intracranial pressure, clot disruption after angiographic procedures)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient and clinician preferences</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Implications for a change in routine anesthetic technique (eg, using total intravenous anesthesia [TIVA] in pediatric patients, who would otherwise receive <a href=\"topic.htm?path=sevoflurane-drug-information\" class=\"drug drug_general\">sevoflurane</a> anesthesia)</p><p/><p class=\"headingAnchor\" id=\"H3330082503\"><span class=\"h3\">High-risk adults</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients at high risk for PONV (ie, those with four risk factors according to Apfel's simplified risk score) should receive three or more interventions (ie, antiemetics, modification of anesthesia, acupuncture) using a multimodal approach [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/43\" class=\"abstract_t\">43</a>]. (See <a href=\"#H440882333\" class=\"local\">'Risk score for postoperative nausea and vomiting for adults'</a> above.)</p><p>In our hospital-based practice of both ambulatory and inpatient surgeries where we have a limited hospital-based drug formulary, our strategy for PONV prophylaxis for high-risk adults is described here. The efficacy of specific interventions is detailed below. (See <a href=\"#H2892527150\" class=\"local\">'Interventions for prophylaxis'</a> below.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Anesthetic technique</strong> &ndash;<strong> </strong>We offer regional anesthesia rather than general anesthesia if appropriate for the surgery. If general anesthesia is required, we prefer TIVA with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Antiemetics </strong>&ndash;<strong> </strong>We usually administer the following antiemetics:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=scopolamine-hyoscine-drug-information\" class=\"drug drug_general\">Scopolamine</a><strong> patch</strong> &ndash; We have the patient apply a scopolamine patch at least two hours prior to the induction of anesthesia, with instructions to remove the patch within 24 hours of application. If necessary, we apply the patch preoperatively. (See <a href=\"#H316232496\" class=\"local\">'Anticholinergics'</a> below.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">Dexamethasone</a> 4 mg intravenously (IV) after induction. (See <a href=\"#H72946217\" class=\"local\">'Glucocorticoids'</a> below.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">Ondansetron</a> 4 mg IV at the end of surgery. (See <a href=\"#H3622478147\" class=\"local\">'Serotonin (5-hydroxytryptamine) receptor antagonists'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Postoperative pain control </strong>&ndash;<strong> </strong>We use a multimodal approach to postoperative pain control, which may include <a href=\"topic.htm?path=acetaminophen-paracetamol-drug-information\" class=\"drug drug_general\">acetaminophen</a> (1 g IV), <a href=\"topic.htm?path=ketorolac-drug-information\" class=\"drug drug_general\">ketorolac</a> (15 to 30 mg IV) after consultation with the surgeon, regional anesthesia techniques, and local anesthetic wound infiltration. (See <a href=\"topic.htm?path=management-of-acute-perioperative-pain#H447933291\" class=\"medical medical_review\">&quot;Management of acute perioperative pain&quot;, section on 'Strategy for perioperative pain control'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Rescue antiemetics</strong> &ndash; If nausea and vomiting occur in the postanesthesia care unit (PACU), we administer an antiemetic from a different class of drug from those used for prophylaxis. Our usual options include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=prochlorperazine-drug-information\" class=\"drug drug_general\">Prochlorperazine</a> 5 to 10 mg IV (see <a href=\"#H978039586\" class=\"local\">'Phenothiazines'</a> below), or</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=droperidol-drug-information\" class=\"drug drug_general\">Droperidol</a> 0.625 mg IV (see <a href=\"#H2984798969\" class=\"local\">'Butyrophenones'</a> below)</p><p/><p class=\"headingAnchor\" id=\"H1924075264\"><span class=\"h3\">High-risk children</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In our hospital-based practice of both ambulatory and inpatient surgeries where we have a limited hospital-based drug formulary, our strategy for PONV prophylaxis for high-risk children (ie, those with history of prior postoperative vomiting (POV), or three to four risk factors according to the Eberhart scoring system) is described here (see <a href=\"#H2088878686\" class=\"local\">'Risk score for postoperative vomiting for children'</a> above). The efficacy of specific interventions is detailed below. (See <a href=\"#H2892527150\" class=\"local\">'Interventions for prophylaxis'</a> below.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Anesthetic technique </strong>&ndash;<strong> </strong>We offer regional anesthesia with sedation to older children. If general anesthesia is required, as it is in most children, we prefer TIVA with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> for very-high-risk patients.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Antiemetics</strong> &ndash; We administer the following antiemetics:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">Dexamethasone</a> 0.25 <span class=\"nowrap\">mg/kg</span> IV, maximum 4 mg (see <a href=\"#H72946217\" class=\"local\">'Glucocorticoids'</a> below)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">Ondansetron</a> 0.1 <span class=\"nowrap\">mg/kg</span> IV, maximum 4 mg (see <a href=\"#H3622478147\" class=\"local\">'Serotonin (5-hydroxytryptamine) receptor antagonists'</a> below)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Postoperative pain control</strong> &ndash; We use a multimodal approach to postoperative pain control, which may include <a href=\"topic.htm?path=dexmedetomidine-drug-information\" class=\"drug drug_general\">dexmedetomidine</a> infusion (0.3 to 1 <span class=\"nowrap\">mcg/kg</span> IV infused over 10 minutes at emergence), <a href=\"topic.htm?path=acetaminophen-paracetamol-drug-information\" class=\"drug drug_general\">acetaminophen</a> (15 <span class=\"nowrap\">mg/kg</span> oral perioperatively, 15 <span class=\"nowrap\">mg/kg</span> IV with maximum 750 mg, 15 to 30 <span class=\"nowrap\">mg/kg</span> rectally, for children 2 to 12 years of age), regional anesthesia techniques, and local anesthetic infiltration.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Rescue antiemetics </strong>&ndash;<strong> </strong>For POV rescue, our usual options include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=dimenhydrinate-drug-information\" class=\"drug drug_general\">Dimenhydrinate</a> or <a href=\"topic.htm?path=diphenhydramine-drug-information\" class=\"drug drug_general\">diphenhydramine</a> 0.5 <span class=\"nowrap\">mg/kg</span> IV, maximum 25 mg (see <a href=\"#H3187996832\" class=\"local\">'Antihistamines'</a> below)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">Ondansetron</a>, repeat dose 0.1 <span class=\"nowrap\">mg/kg</span> IV, maximum 4 mg, total perioperative maximum 8 mg (see <a href=\"#H3622478147\" class=\"local\">'Serotonin (5-hydroxytryptamine) receptor antagonists'</a> below)</p><p/><p class=\"headingAnchor\" id=\"H2609076195\"><span class=\"h3\">Moderate-risk adults</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Adults with two or three risk factors according to Apfel's simplified risk score are at moderate risk of PONV. For these patients, we choose one or two interventions, either modification of the anesthetic technique (ie, regional anesthesia, or TIVA with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>), administration of an antiemetic, or acupuncture. (See <a href=\"#H1499538518\" class=\"local\">'Reduction of baseline risk'</a> below and <a href=\"#H144014180\" class=\"local\">'Antiemetics'</a> below and <a href=\"#H959820222\" class=\"local\">'Nonpharmacologic techniques'</a> below.)</p><p class=\"headingAnchor\" id=\"H495765039\"><span class=\"h3\">Moderate-risk children</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children at moderate risk of POV include those who undergo ear nose and throat, ophthalmologic, or gastrointestinal diagnostic procedures, undergo anesthetics &gt;2 hours long, or require large doses of opioids (ie, <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> &ge;0.2 <span class=\"nowrap\">mg/kg</span> IV or <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> &ge;5 to 10 <span class=\"nowrap\">mcg/kg</span> IV). (See <a href=\"#H2088878686\" class=\"local\">'Risk score for postoperative vomiting for children'</a> above.)</p><p>We treat moderate-risk children as we would high-risk children, as described above, without using TIVA. (See <a href=\"#H1924075264\" class=\"local\">'High-risk children'</a> above.)</p><p class=\"headingAnchor\" id=\"H3213524084\"><span class=\"h3\">Low-risk adults and children</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prophylaxis for PONV for low-risk adults and children should be based on clinician and patient preferences, formulary choices, and cost.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Adults </strong>&ndash;<strong> </strong>For adults with zero or one risk factor for PONV, we usually administer <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> 4 mg IV at the end of surgery for patients who receive general inhalation anesthesia or TIVA that includes opioids, given the drug's low side effect profile and cost. Alternatively, it is reasonable to administer no prophylactic antiemetic for these patients, and to promptly treat PONV if it occurs.</p><p/><p class=\"bulletIndent1\">For low-risk adults who receive TIVA with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> without opioid, we do not usually administer PONV prophylaxis, though others do.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Children </strong>&ndash;<strong> </strong>For children with zero or one risk factor for POV, we administer <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> 0.1 <span class=\"nowrap\">mg/kg</span> IV, maximum 4 mg. For rescue antiemetic, we administer <a href=\"topic.htm?path=dimenhydrinate-drug-information\" class=\"drug drug_general\">dimenhydrinate</a> or <a href=\"topic.htm?path=diphenhydramine-drug-information\" class=\"drug drug_general\">diphenhydramine</a> 0.5 <span class=\"nowrap\">mg/kg</span> IV, maximum 25 mg, or ondansetron, repeat dose 0.1 <span class=\"nowrap\">mg/kg</span> IV, maximum 4 mg, total perioperative maximum 8 mg.</p><p/><p class=\"headingAnchor\" id=\"H2892527150\"><span class=\"h2\">Interventions for prophylaxis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All patients should receive a multimodal, opioid-sparing approach for effective postoperative pain control. The strategy for prevention of PONV is shown in an algorithm (<a href=\"image.htm?imageKey=ANEST%2F111057\" class=\"graphic graphic_algorithm graphicRef111057 \">algorithm 1</a> and <a href=\"image.htm?imageKey=SURG%2F65891\" class=\"graphic graphic_table graphicRef65891 \">table 1</a>). (See <a href=\"#H1499538518\" class=\"local\">'Reduction of baseline risk'</a> below and <a href=\"#H144014180\" class=\"local\">'Antiemetics'</a> below and <a href=\"#H959820222\" class=\"local\">'Nonpharmacologic techniques'</a> below.)</p><p class=\"headingAnchor\" id=\"H1499538518\"><span class=\"h3\">Reduction of baseline risk</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The baseline risk of PONV and POV may be reduced as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Modification of anesthetic technique</strong> &ndash;<strong> </strong>(See <a href=\"#H2162413264\" class=\"local\">'Anesthetic factors'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Use of regional anesthesia rather than general anesthesia</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Use of TIVA with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>, rather than volatile anesthetics</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Adequate hydration </strong>&ndash;<strong> </strong>In clinical practice, decisions regarding IV fluid administration in adults are usually based on factors other than the risk of PONV. The literature on the effect of the type and amount of IV fluid on PONV in adults is conflicting. A meta-analysis of 15 randomized trials including approximately 1600 patients found that liberal intraoperative crystalloid administration (15 to 30 <span class=\"nowrap\">mL/kg)</span> reduced the risk of late and overall PONV but not early PONV compared with restrictive IV fluids (0 to 2 <span class=\"nowrap\">mL/kg)</span> [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/44\" class=\"abstract_t\">44</a>]. </p><p/><p class=\"bulletIndent1\">Liberal fluid administration may be beneficial in children for prevention of PONV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/45,46\" class=\"abstract_t\">45,46</a>]. In a randomized, double-blind trial of 100 pediatric patients undergoing strabismus surgery, the group of patients that received 30 <span class=\"nowrap\">mL/kg/hour</span> of lactated Ringer's solution (LR) intraoperatively had decreased PONV within the first 24 hours after surgery compared with the control group, who received 10 <span class=\"nowrap\">mL/kg/hour</span> of LR [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/45\" class=\"abstract_t\">45</a>]. In our practice, we consider administration of liberal amounts of IV fluid for children who have had POV despite multiple preventive strategies with prior anesthetics. Intraoperative fluid management is discussed separately. (See <a href=\"topic.htm?path=intraoperative-fluid-management\" class=\"medical medical_review\">&quot;Intraoperative fluid management&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Intravenous dextrose solution &mdash; </strong>Studies of the effect of perioperative administration of intravenous (IV) dextrose solutions on PONV have reported mixed results. In one study that included 100 patients who underwent laparoscopic cholecystectomy, patients were randomly assigned to receive an infusion of 5% dextrose (D5) or normal saline (NS) started after removal of the gallbladder, without prophylaxis for PONV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/47\" class=\"abstract_t\">47</a>]. Patients who received D5 had less PONV within 24 hours of surgery than patients who received NS (28 percent versus 66 percent), and required less rescue antiemetics. Similarly, in two studies of patients at high risk of PONV, patients who received 1000 mL of dextrose containing IV fluid in the PACU had less need for rescue antiemetics [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/48\" class=\"abstract_t\">48</a>] and lower incidence of PONV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/49\" class=\"abstract_t\">49</a>] than patients who received 1000 mL of Ringer&rsquo;s Lactate (RL). In contrast, in two other studies, an infusion of dextrose during emergence from anesthesia [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/50\" class=\"abstract_t\">50</a>] and fluid loading with a dextrose solution after induction of anesthesia [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/51\" class=\"abstract_t\">51</a>] did not reduce the incidence of PONV. </p><p/><p class=\"bulletIndent1\">Further study is required before recommending the routine administration of dextrose solutions to prevent PONV. Intraoperative administration of IV dextrose solutions can cause hyperglycemia, even in nondiabetic patients [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/52\" class=\"abstract_t\">52</a>]. In one study mentioned above, mean blood glucose after the infusion of D5 was 282 <span class=\"nowrap\">mg/dL,</span> versus 92 <span class=\"nowrap\">mg/dL</span> after infusion of RL [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/49\" class=\"abstract_t\">49</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Multimodal postoperative pain control </strong>&ndash;<strong> </strong>A multimodal strategy for postoperative pain control including regional anesthesia techniques, <a href=\"topic.htm?path=acetaminophen-paracetamol-drug-information\" class=\"drug drug_general\">acetaminophen</a>, nonsteroidal antiinflammatory drugs (NSAIDs), and other nonopioid adjuvants may reduce the need for postoperative opioids and the risk of PONV and POV. (See <a href=\"#H2162413264\" class=\"local\">'Anesthetic factors'</a> above and <a href=\"topic.htm?path=management-of-acute-perioperative-pain#H447933291\" class=\"medical medical_review\">&quot;Management of acute perioperative pain&quot;, section on 'Strategy for perioperative pain control'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H144014180\"><span class=\"h3\">Antiemetics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A variety of antiemetics acting via different mechanisms are used for prevention and treatment of PONV. In general, clinicians choose among these agents based upon side effect profile, personal experience, cost, and formulary considerations.</p><p>The mechanisms of action of antiemetics are discussed separately. (See <a href=\"topic.htm?path=characteristics-of-antiemetic-drugs\" class=\"medical medical_review\">&quot;Characteristics of antiemetic drugs&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2430614242\"><span class=\"h4\">General principles</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following principles apply to the use of antiemetics in this setting:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Commonly used antiemetics reduce the risk of PONV by approximately 25 percent [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/53\" class=\"abstract_t\">53</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The absolute benefit of an antiemetic depends on the degree of baseline risk, with higher-risk patients benefiting more than low-risk patients [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/53\" class=\"abstract_t\">53</a>]. As examples, for a patient with a baseline risk of PONV of 80 percent (eg, a female nonsmoker with a history of motion sickness who requires postoperative opioids), <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> would reduce the risk of PONV by approximately 20 percent to a risk of 60 percent. By contrast, for a patient with baseline risk of 10 percent (eg, a male smoker without motion sickness who does not require postoperative opioids), ondansetron would reduce the risk of PONV by only 2.5 percent, to a risk of 7.5 percent.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The effects of drugs that act on different receptors are additive rather than synergistic. Because each drug reduces PONV by a fraction of the existing risk, each added drug results in less antiemetic benefit [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/53\" class=\"abstract_t\">53</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The antiemetic benefit from TIVA with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> is approximately the same as administration of one antiemetic with volatile inhalation anesthesia [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/53\" class=\"abstract_t\">53</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>All antiemetics have side effects, some more serious than others (eg, headache, sedation, electrocardiogram [ECG] QT interval prolongation). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rescue treatment should include an antiemetic from a different class than the drugs that were used for prophylaxis unless the effect of the previous drug has likely worn off.</p><p/><p>Commonly used antiemetics are described in the following sections (<a href=\"image.htm?imageKey=SURG%2F65891\" class=\"graphic graphic_table graphicRef65891 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H3622478147\"><span class=\"h4\">Serotonin (5-hydroxytryptamine) receptor antagonists</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The 5-hydroxytryptamine type 3 (5-HT<sub>3</sub>) receptor antagonists are commonly used for prevention and treatment of PONV. Their lack of sedative effects is an advantage in the postoperative period; some clinicians avoid the 5-HT<sub>3 </sub>antagonists intraoperatively to save these drugs for possible rescue in the PACU.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>First-generation serotonin antagonists </strong>&ndash;<strong> </strong>The first-generation serotonin antagonists (ie, <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a>, <a href=\"topic.htm?path=granisetron-drug-information\" class=\"drug drug_general\">granisetron</a>, and, outside the United States, <a href=\"topic.htm?path=dolasetron-drug-information\" class=\"drug drug_general\">dolasetron</a>, ramosetron, and tropisetron) are equally efficacious for PONV at equipotent doses (relative risk [RR] 0.76 versus placebo) [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/54\" class=\"abstract_t\">54</a>]. All of these drugs have potential to prolong the electrocardiogram intervals, particularly the QT interval, and should be avoided for patients at risk for QTc prolongation. These agents are administered as a single dose at the end of surgery. Ondansetron is available as an orally disintegrating film (ODF), which is as effective as IV ondansetron [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/55\" class=\"abstract_t\">55</a>]. The ODF may be useful for postdischarge administration and may be administered to children over the age of five [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/56\" class=\"abstract_t\">56</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">Ondansetron</a> &ndash; Adults 4 mg IV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/53,57-59\" class=\"abstract_t\">53,57-59</a>], children 0.1 <span class=\"nowrap\">mg/kg</span> IV, maximum 4 mg [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/60\" class=\"abstract_t\">60</a>]</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=granisetron-drug-information\" class=\"drug drug_general\">Granisetron</a> &ndash; Adults 1 mg IV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/61\" class=\"abstract_t\">61</a>], children 40 <span class=\"nowrap\">mcg/kg</span> IV, maximum 0.6 mg [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/62\" class=\"abstract_t\">62</a>]</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=dolasetron-drug-information\" class=\"drug drug_general\">Dolasetron</a> &ndash; Adults 12.5 mg IV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/63\" class=\"abstract_t\">63</a>], children 0.35 <span class=\"nowrap\">mg/kg</span> IV, maximum 12.5 mg</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=palonosetron-drug-information\" class=\"drug drug_general\">Palonosetron</a><strong> </strong>&ndash;<strong> </strong>Palonosetron is the newest serotonin antagonist. Compared with the first-generation drugs in this class, palonosetron has unique and higher receptor binding affinity [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/64\" class=\"abstract_t\">64</a>], and a longer half-life of 40 hours [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/65\" class=\"abstract_t\">65</a>], with similar efficacy for prevention of PONV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/66,67\" class=\"abstract_t\">66,67</a>]. Because of its prolonged action, palonosetron may be particularly effective for prevention of late or postdischarge nausea and vomiting (PDNV). Palonosetron does not appear to affect the QT interval.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=palonosetron-drug-information\" class=\"drug drug_general\">Palonosetron</a><strong> dose</strong> &ndash; Adults 0.075 mg IV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/66\" class=\"abstract_t\">66</a>] at the end of surgery, children 2.5 mcg IV (limited data)</p><p/><p class=\"headingAnchor\" id=\"H72946217\"><span class=\"h4\">Glucocorticoids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">Dexamethasone</a> is as effective as <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> and <a href=\"topic.htm?path=droperidol-drug-information\" class=\"drug drug_general\">droperidol</a> for prevention of PONV (RR 0.76 versus placebo) [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/53,68,69\" class=\"abstract_t\">53,68,69</a>], and is the most commonly used and studied corticosteroid for POV prophylaxis in children [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/70\" class=\"abstract_t\">70</a>].</p><p><a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">Dexamethasone</a> may be beneficial because of a direct antiemetic effect and by reducing postoperative pain and the need for postoperative opioids. Lower doses of dexamethasone may be required for PONV prophylaxis than for pain relief. A meta-analysis of 60 randomized trials with 6700 patients found that a dose of 4 to 5 mg IV dexamethasone was as effective as 8 to 10 mg IV for reduction of PONV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/71\" class=\"abstract_t\">71</a>]. By contrast, two meta-analyses of studies comparing lower-dose (&lt;0.1 <span class=\"nowrap\">mg/kg</span> IV) dexamethasone with higher doses (&gt;0.1 <span class=\"nowrap\">mg/kg)</span> found that higher doses were required for reduced opioid requirement [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/72,73\" class=\"abstract_t\">72,73</a>].</p><p>Data on the safety of prophylactic <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> are inconclusive, and the use of dexamethasone should be individualized. (See <a href=\"topic.htm?path=anesthesia-for-tonsillectomy-with-or-without-adenoidectomy-in-children#H27778756\" class=\"medical medical_review\">&quot;Anesthesia for tonsillectomy with or without adenoidectomy in children&quot;, section on 'Dexamethasone'</a>.)</p><p>Most studies have shown no increase in wound infection with one dose of <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/74-77\" class=\"abstract_t\">74-77</a>]. Dexamethasone may be relatively contraindicated in patients with impaired glucose tolerance. Serum glucose may rise for 6 to 12 hours after dexamethasone administration in such patients [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/78-80\" class=\"abstract_t\">78-80</a>]. In pediatric oncology patients who undergo anesthesia for bone marrow biopsy or lumbar puncture, glucocorticoids can interfere with cell counts and, ultimately, chemotherapeutic management or, rarely, can cause tumor lysis syndrome [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/43\" class=\"abstract_t\">43</a>]. The patient's oncologist should be consulted prior to administration of dexamethasone. (See <a href=\"topic.htm?path=tumor-lysis-syndrome-definition-pathogenesis-clinical-manifestations-etiology-and-risk-factors\" class=\"medical medical_review\">&quot;Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors&quot;</a>.)</p><p>Because of its slow onset, <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> is more effective if administered after induction rather than at the end of surgery [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/68\" class=\"abstract_t\">68</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">Dexamethasone</a><strong> dose</strong> &ndash; Adults, 4 mg IV after induction, children 0.25 <span class=\"nowrap\">mg/kg,</span> maximum 4 mg [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/81\" class=\"abstract_t\">81</a>]</p><p/><p class=\"headingAnchor\" id=\"H316232496\"><span class=\"h4\">Anticholinergics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=scopolamine-hyoscine-drug-information\" class=\"drug drug_general\">Scopolamine</a> is an anticholinergic medication that may be administered IV, but is usually applied as a 1.5-mg transdermal preparation for PONV prophylaxis. Transdermal scopolamine (TDS) is a sustained-release, long-acting patch that is applied at least several hours prior to anesthesia, and is as effective as <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> and <a href=\"topic.htm?path=droperidol-drug-information\" class=\"drug drug_general\">droperidol</a> for PONV prophylaxis [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/82\" class=\"abstract_t\">82</a>]. A meta-analysis of 25 randomized trials with 3300 patients found that TDS was associated with a reduced risk of PONV (RR 0.73) compared with placebo during the first 24 hours after anesthesia [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/83\" class=\"abstract_t\">83</a>]. TDS was as effective if applied the evening prior to surgery as when applied two to four hours prior to anesthesia. The side effects of scopolamine are mild, and include dry mouth and blurry vision [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/83,84\" class=\"abstract_t\">83,84</a>]. Confusion or agitation may occur, especially in older adults with baseline cognitive impairment [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/85,86\" class=\"abstract_t\">85,86</a>].</p><p class=\"headingAnchor\" id=\"H2984798969\"><span class=\"h4\">Butyrophenones</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The butyrophenone class of antiemetics includes <a href=\"topic.htm?path=droperidol-drug-information\" class=\"drug drug_general\">droperidol</a> and <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a>. Low doses of both of these drugs are as effective as <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> for PONV prophylaxis (droperidol 1.25 mg IV; RR 0.74 versus placebo) [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/87,88\" class=\"abstract_t\">87,88</a>]. The US Food and Drug Administration (FDA) issued a &quot;black box&quot; warning regarding the potential for sudden cardiac death with droperidol in 2001. Since then, droperidol has rarely been used in the United States, though at the doses recommended for PONV prophylaxis, the risk of adverse cardiac events is extremely low. The butyrophenones are associated with an increase in the QT interval to a degree that is similar to ondansetron [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/89\" class=\"abstract_t\">89</a>]. Administration of ondansetron with droperidol or with haloperidol is more effective for PONV than either drug alone, without additional QT prolongation [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/90-92\" class=\"abstract_t\">90-92</a>]. Similar to ondansetron, butyrophenones should be avoided for patients at increased risk of QT prolongation (<a href=\"image.htm?imageKey=CARD%2F57431\" class=\"graphic graphic_table graphicRef57431 \">table 2</a>).</p><p>Both <a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">haloperidol</a> and <a href=\"topic.htm?path=droperidol-drug-information\" class=\"drug drug_general\">droperidol</a> are typically administered as a single dose at the end of surgery. Haloperidol may also be administered orally or intramuscularly (IM). These drugs are not administered for POV prophylaxis for children.</p><p>For patients who receive <a href=\"topic.htm?path=droperidol-drug-information\" class=\"drug drug_general\">droperidol</a>, we follow the FDA recommendation to monitor ECG for arrhythmias for two to three hours after administration [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/89\" class=\"abstract_t\">89</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=droperidol-drug-information\" class=\"drug drug_general\">Droperidol</a> &ndash; 0.625 to 1.25 mg IV</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=haloperidol-drug-information\" class=\"drug drug_general\">Haloperidol</a> &ndash; 1 mg IV, or 1 mg oral, or 1 mg IM</p><p/><p class=\"headingAnchor\" id=\"H766421411\"><span class=\"h4\">Neurokinin 1 receptor antagonists</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The neurokinin receptor antagonists comprise a relatively new class of long-acting antiemetics that may be especially effective for prevention of PONV and PDNV.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=aprepitant-drug-information\" class=\"drug drug_general\">Aprepitant</a><strong> </strong>&ndash; Aprepitant is the neurokinin 1 (NK1) receptor antagonist available in the United States. It is available in oral form and as a parenteral version, <a href=\"topic.htm?path=fosaprepitant-drug-information\" class=\"drug drug_general\">fosaprepitant</a>. Aprepitant has a half-life of 40 hours [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/43\" class=\"abstract_t\">43</a>]. Compared with <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> alone [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/93,94\" class=\"abstract_t\">93,94</a>], and compared with ondansetron when both drugs have been administered with <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/95\" class=\"abstract_t\">95</a>], aprepitant has been found to be equally effective for prevention of postoperative nausea and more effective for preventing vomiting at 24 and 48 hours. Experience with aprepitant is limited, especially in children, and further study is required before recommending its use for routine prophylaxis.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=aprepitant-drug-information\" class=\"drug drug_general\">Aprepitant</a><strong> dose</strong> &ndash; Adults, 80 mg oral preoperatively</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rolapitant-drug-information\" class=\"drug drug_general\">Rolapitant</a><strong> </strong>&ndash;<strong> </strong>Rolapitant is a new long-acting NK1 antagonist that is available in the United States as of September 2015 in oral-form 90-mg tabs, and in October 2017 as an injectable emulsion for prevention of chemotherapy induced nausea and vomiting (166.5 mg IV injected over 30 minutes). Rolapitant may be particularly effective for PDNV because of its very long half-life of 180 hours. A prospective dose ranging study of 600 high-risk patients reported that doses of &ge;70 mg orally reduced emesis at 72 and 120 hours compared with placebo and with <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/96\" class=\"abstract_t\">96</a>]. The intravenous preparation has not been studied for PONV prophylaxis.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=rolapitant-drug-information\" class=\"drug drug_general\">Rolapitant</a><strong> dose</strong> &ndash; Adults, 90 mg oral, preoperatively [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/96\" class=\"abstract_t\">96</a>]</p><p/><p class=\"headingAnchor\" id=\"H3187996832\"><span class=\"h4\">Antihistamines</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dimenhydrinate-drug-information\" class=\"drug drug_general\">Dimenhydrinate</a> and <a href=\"topic.htm?path=diphenhydramine-drug-information\" class=\"drug drug_general\">diphenhydramine</a> are antihistamines with antiemetic efficacy similar to reported efficacy for <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>, <a href=\"topic.htm?path=droperidol-drug-information\" class=\"drug drug_general\">droperidol</a>, and the 5-HT<sub>3</sub> antagonists at a dose of 1 <span class=\"nowrap\">mg/kg</span> IV for adults, and 0.5 <span class=\"nowrap\">mg/kg,</span> maximum 25 mg in children [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/97\" class=\"abstract_t\">97</a>], though direct comparisons have not been done. Dimenhydrinate can also be administered IM, orally, and rectally. Dose responses and optimal timing of administration have not been established.</p><p>Common side effects of <a href=\"topic.htm?path=dimenhydrinate-drug-information\" class=\"drug drug_general\">dimenhydrinate</a> include sedation, dry mouth, dizziness, and urinary retention. In children, concerns for sedation and the possibility of emergence delirium related to urinary retention have limited the routine use of this drug.</p><p class=\"headingAnchor\" id=\"H978039586\"><span class=\"h4\">Phenothiazines</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The phenothiazines as a group are most effective at treating opioid-induced nausea and vomiting. Their use for PONV is limited by sedation at high doses and extrapyramidal effects. Data are limited regarding optimal doses and timing of administration. These drugs are not usually administered for children for POV prophylaxis.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=perphenazine-drug-information\" class=\"drug drug_general\">Perphenazine</a><strong> </strong>&ndash;<strong> </strong>5 mg IV in adults, 0.07 <span class=\"nowrap\">mg/kg</span> IV in children [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/98\" class=\"abstract_t\">98</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=promethazine-drug-information\" class=\"drug drug_general\">Promethazine</a><strong> </strong>&ndash;<strong> </strong>6.25 to 12.5 mg IV at induction of anesthesia [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/99,100\" class=\"abstract_t\">99,100</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=prochlorperazine-drug-information\" class=\"drug drug_general\">Prochlorperazine</a><strong> </strong>&ndash;<strong> </strong>5 to 10 mg IV at the end of surgery [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/101\" class=\"abstract_t\">101</a>]</p><p/><p class=\"headingAnchor\" id=\"H4207421783\"><span class=\"h4\">Propofol</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">Propofol</a> is a sedative hypnotic that is used for induction and maintenance of anesthesia and for sedation. Propofol is an antiemetic when administered at doses required for induction and maintenance for TIVA [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/53,102-105\" class=\"abstract_t\">53,102-105</a>] and when administered at subhypnotic doses in adults [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/106\" class=\"abstract_t\">106</a>] and children [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/107\" class=\"abstract_t\">107</a>].</p><p>In one study, 80 children who underwent tonsillectomy with <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> PONV prophylaxis were randomly assigned to receive a <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> bolus (1 <span class=\"nowrap\">mg/kg</span> IV) followed by low-dose infusion (20 <span class=\"nowrap\">mcg/kg/minute</span> IV) until the end of surgery, or no propofol [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/107\" class=\"abstract_t\">107</a>]. A higher percentage of those assigned to propofol were free of vomiting or retching for the initial 24 hours after surgery (75 versus 38 percent).</p><p class=\"headingAnchor\" id=\"H3571900129\"><span class=\"h4\">Metoclopramide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=metoclopramide-drug-information\" class=\"drug drug_general\">Metoclopramide</a> is a relatively weak antiemetic that is rarely administered as PONV prophylaxis in adults or children.</p><p>The literature on the efficacy of <a href=\"topic.htm?path=metoclopramide-drug-information\" class=\"drug drug_general\">metoclopramide</a> as an antiemetic for PONV is controversial. A number of published studies of antiemetics from a single author have been retracted from publication, including studies on metoclopramide [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/108\" class=\"abstract_t\">108</a>]. Meta-analyses including some of those studies had reported that metoclopramide was ineffective for prevention of PONV. However, a subsequent meta-analysis that excluded the retracted studies found that the usual adult dose of metoclopramide of 10 mg IV reduced the incidence of 24-hour PONV (odds ratio [OR] 0.58) [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/109\" class=\"abstract_t\">109</a>]. However, metoclopramide in usual doses is not as effective as other commonly used antiemetics. In a meta-analysis of trials (without the retracted studies) comparing antiemetics, <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> was found to be 57 percent more effective than metoclopramide 10 mg IV for PONV prevention [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/87\" class=\"abstract_t\">87</a>].</p><p>In addition, studies in both adults [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/36\" class=\"abstract_t\">36</a>] and children [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/39\" class=\"abstract_t\">39</a>] report that <a href=\"topic.htm?path=metoclopramide-drug-information\" class=\"drug drug_general\">metoclopramide</a> is effective only at doses higher than usually used (25 to 50 mg IV in adults, 0.15 to 0.25 <span class=\"nowrap\">mg/kg</span> in children). We typically do not administer these high doses because of increasing risk of adverse effects including hypotension, tachycardia, and rarely extrapyramidal symptoms.</p><p>Extrapyramidal symptoms may be as much as 20-fold more common in children compared with adults [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/110\" class=\"abstract_t\">110</a>]. In infants, prolonged clearance may increase serum concentrations of <a href=\"topic.htm?path=metoclopramide-drug-information\" class=\"drug drug_general\">metoclopramide</a>; administration should be avoided for children &lt;1 year of age. In older children, metoclopramide should only be administered when other antiemetics cannot be used, at a dose of 0.1 <span class=\"nowrap\">mg/kg</span> IV, maximum 10 mg. (See <a href=\"topic.htm?path=metoclopramide-pediatric-drug-information\" class=\"drug drug_pediatric\">&quot;Metoclopramide: Pediatric drug information&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H4194392610\"><span class=\"h4\">Midazolam</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The literature on the efficacy of <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a> for PONV prophylaxis is inconclusive. Meta-analyses of trials of perioperative midazolam have reported 38 to 55 percent reduction in overall PONV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/111,112\" class=\"abstract_t\">111,112</a>]. However, there was high risk of bias in the included studies, and a clinically relevant increase in postoperative sedation could not be ruled out.</p><p>We do not administer <a href=\"topic.htm?path=midazolam-drug-information\" class=\"drug drug_general\">midazolam</a> solely for PONV prophylaxis because of the potential for postoperative sedation and delirium in some patient populations (eg, older adults, mentally ill).</p><p class=\"headingAnchor\" id=\"H2447268839\"><span class=\"h3\">Combination therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Combination therapy using different classes of drugs is usually more effective than single-drug therapy for PONV prophylaxis in both children and adults [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/53,90,113-120\" class=\"abstract_t\">53,90,113-120</a>]. This concept was demonstrated by a large randomized trial of six interventions for PONV prophylaxis, including three antiemetics (<a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>, <a href=\"topic.htm?path=droperidol-drug-information\" class=\"drug drug_general\">droperidol</a>, and <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a>) alone and in combination [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/53\" class=\"abstract_t\">53</a>]. Each antiemetic reduced PONV to a similar extent (RR 26 percent), and each drug acted independently, such that the risk reduction from combinations could be estimated by multiplying individual risk reductions.</p><p>The most common POV prevention strategy for children combines <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> and <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a>. In children undergoing surgery for strabismus, the addition of ondansetron to dexamethasone reduces POV from 23 to 5 percent [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/121\" class=\"abstract_t\">121</a>].</p><p class=\"headingAnchor\" id=\"H959820222\"><span class=\"h3\">Nonpharmacologic techniques</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of nonpharmacologic methods have been suggested and studied for PONV prophylaxis. Of these, acupuncture seems to be the most promising.</p><p class=\"headingAnchor\" id=\"H695815149\"><span class=\"h4\">Acupuncture</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Stimulation of the pericardium-6 (P-6) acupuncture point may be effective for PONV prophylaxis for clinicians familiar with this technique (<a href=\"image.htm?imageKey=ANEST%2F107138\" class=\"graphic graphic_picture graphicRef107138 \">picture 1</a>). A meta-analysis of 59 studies including 7700 adults and children reported that acupoint stimulation with a variety of techniques (eg, acupuncture needles, acupressure wristbands) was as effective as the commonly used antiemetics for prevention of PONV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/122\" class=\"abstract_t\">122</a>].</p><p>The side effects of acupuncture and acupressure are low, including skin redness or irritation and, very rarely, nerve damage, bleeding, or skin infection [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/123\" class=\"abstract_t\">123</a>].</p><p class=\"headingAnchor\" id=\"H959820240\"><span class=\"h4\">Isopropyl alcohol</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Inhalation of isopropyl alcohol (eg, having the patient inhale alcohol from a skin prep pack or alcohol-soaked sponge) may be a modestly effective short-term treatment for PONV. A meta-analysis including six small studies found that alcohol inhalation reduced the need for rescue antiemetics compared with placebo, but that it was less effective than standard antiemetics [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/124\" class=\"abstract_t\">124</a>].</p><p>Isopropyl alcohol is a readily available, low-risk treatment that may be most useful for immediate administration while other antiemetics are prepared for administration.</p><p class=\"headingAnchor\" id=\"H2230341374\"><span class=\"h1\">RESCUE THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>When postoperative nausea and vomiting (PONV) occurs in the postanesthesia care unit (PACU) or operating room, rescue treatment should include a drug from a different class than those that have already been administered unless the effect of the first drug has worn off or a potentially inadequate dose has been administered.</p><p>The serotonin receptor antagonists are particularly beneficial as rescue drugs in the PACU, especially for same-day surgery patients, because they are nonsedating.</p><p>For opioid-induced PONV or postoperative vomiting (POV), low-dose <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> infusion (0.25 <span class=\"nowrap\">mcg/kg/hour</span> IV) can reduce opioid-induced side effects in children and adolescents, including nausea and vomiting, without affecting analgesia [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/125\" class=\"abstract_t\">125</a>].</p><p class=\"headingAnchor\" id=\"H959820332\"><span class=\"h1\">POSTDISCHARGE NAUSEA AND VOMITING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Postdischarge nausea and vomiting (PDNV) (ie, nausea and vomiting within 48 hours of discharge) occurs in 37 percent of adult patients who undergo general anesthesia for same-day surgery [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/21\" class=\"abstract_t\">21</a>]. Risk factors for PDNV include those that predict PONV [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/126\" class=\"abstract_t\">126</a>] and, in addition, administration of opioids in the PACU and nausea in the PACU. A simplified risk scoring system has been developed for PDNV, including the following risk factors (<a href=\"image.htm?imageKey=ANEST%2F107494\" class=\"graphic graphic_figure graphicRef107494 \">figure 3</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Female gender</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Age &lt;50</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>History of PONV</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Opioids administered in the PACU</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nausea in the PACU</p><p/><p>Zero, one, two, three, four, and five risk factors are associated with a 7, 20, 28, 53, 60, and 90 percent incidence of PDNV, respectively [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/21\" class=\"abstract_t\">21</a>].</p><p>Preventive strategies for PDNV include risk stratification followed by a multimodal prophylactic approach, similar to prophylaxis for PONV. Other options may be limited by availability of the newer antiemetics and formulary issues. The addition of either long-acting antiemetics (eg, <a href=\"topic.htm?path=aprepitant-drug-information\" class=\"drug drug_general\">aprepitant</a>, <a href=\"topic.htm?path=palonosetron-drug-information\" class=\"drug drug_general\">palonosetron</a>, transdermal <a href=\"topic.htm?path=scopolamine-hyoscine-drug-information\" class=\"drug drug_general\">scopolamine</a>) or repeat, scheduled dosing of shorter-acting medications in the postoperative period (eg, oral disintegrating <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> [ODO]) may reduce PDNV.</p><p>In one study, high-risk patients were randomly assigned to standard prophylaxis with <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> 4 mg intravenously (IV), or a study regimen including <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> 8 mg IV and ondansetron 4 mg IV intraoperatively, and ODO 8 mg to be taken on discharge and in the morning of postoperative days 1 and 2 [<a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/127\" class=\"abstract_t\">127</a>]. The study regimen reduced the incidence of postdischarge nausea (20 percent versus 57 percent) and vomiting (3 percent versus 20 percent) compared with standard prophylaxis.</p><p class=\"headingAnchor\" id=\"H2737199774\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-postoperative-nausea-and-vomiting\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Postoperative nausea and vomiting&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=nausea-and-vomiting-after-surgery-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Nausea and vomiting after surgery (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H959820338\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Postoperative nausea and vomiting (PONV) is a patient-important outcome that occurs in approximately 30 percent of adults and children after general anesthesia, and may occur in as many as 80 percent of high-risk patients. (See <a href=\"#H712007825\" class=\"local\">'Risk factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The preventive strategy for PONV should include patient risk stratification and prophylactic interventions based on the individual patient's risk.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient-related risk factors for PONV in adults and postoperative vomiting (POV) in children include the following (see <a href=\"#H3592868051\" class=\"local\">'Patient risk factors'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Adults</strong> &ndash; Female gender, a history of PONV or motion sickness, nonsmoking, age &lt;50</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Children</strong> &ndash; Age &gt;3 years until puberty, history of POV or PONV in a parent or sibling</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anesthesia-related risk factors include the following (see <a href=\"#H2162413264\" class=\"local\">'Anesthetic factors'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Use of general anesthesia </p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Administration of volatile anesthetics rather than <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a></p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Longer anesthesia with volatile anesthetics</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Administration of <a href=\"topic.htm?path=nitrous-oxide-drug-information\" class=\"drug drug_general\">nitrous oxide</a> (N<sub>2</sub>O) in high-risk patients</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Postoperative opioid administration</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Some surgical procedures are associated with an increased risk of PONV and POV, including the following (see <a href=\"#H2012868701\" class=\"local\">'Type of surgery'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Adults</strong> &ndash; Cholecystectomy, gynecologic procedures, laparoscopy</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Children</strong> &ndash; Strabismus surgery, adenotonsillectomy</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Scoring systems have been developed to stratify the risk of PONV in adults and POV in children.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We use Apfel's simplified risk score to evaluate adults. This risk score includes four factors: female gender, nonsmoking, history of motion sickness or PONV, and expected administration of postoperative opioids. (See <a href=\"#H440882333\" class=\"local\">'Risk score for postoperative nausea and vomiting for adults'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>We use an alternative risk scoring system for children, which includes four risk factors: age &gt;3 years, duration of surgery &gt;30 minutes, strabismus surgery, and history of POV or a relative with <span class=\"nowrap\">POV/PONV</span>. (See <a href=\"#H2088878686\" class=\"local\">'Risk score for postoperative vomiting for children'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prophylaxis for PONV and POV for all patients should include multimodal, opioid-sparing postoperative pain control. Additional prophylactic interventions may include the following (<a href=\"image.htm?imageKey=ANEST%2F111057\" class=\"graphic graphic_algorithm graphicRef111057 \">algorithm 1</a> and <a href=\"image.htm?imageKey=SURG%2F65891\" class=\"graphic graphic_table graphicRef65891 \">table 1</a>):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Modification of the anesthetic (see <a href=\"#H1499538518\" class=\"local\">'Reduction of baseline risk'</a> above)</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Avoid general anesthesia</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Use total intravenous anesthesia (TIVA) with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a></p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Antiemetics (see <a href=\"#H144014180\" class=\"local\">'Antiemetics'</a> above)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Acupuncture (see <a href=\"#H695815149\" class=\"local\">'Acupuncture'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A variety of antiemetics may be administered for prophylaxis and treatment of PONV (<a href=\"image.htm?imageKey=SURG%2F65891\" class=\"graphic graphic_table graphicRef65891 \">table 1</a>). (See <a href=\"#H144014180\" class=\"local\">'Antiemetics'</a> above.)</p><p/><p class=\"bulletIndent1\">General principles for their use include the following (see <a href=\"#H2430614242\" class=\"local\">'General principles'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The most commonly used antiemetics reduce the risk of PONV by approximately 25 percent.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The absolute benefit of an antiemetic depends on the degree of baseline risk, with higher-risk patients benefiting more than low-risk patients.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The effects of drugs that act on different receptors are additive.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>All antiemetics have side effects, some more serious than others.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients at high risk of PONV should receive more than two prophylactic interventions (ie, modification of the anesthetic, antiemetics, acupuncture) using a multimodal approach. (See <a href=\"#H2892527150\" class=\"local\">'Interventions for prophylaxis'</a> above.)</p><p/><p class=\"bulletIndent1\">For high-risk adults (ie, with four risk factors), we prefer regional anesthesia if possible or TIVA with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> if general anesthesia is required, and we administer transdermal <a href=\"topic.htm?path=scopolamine-hyoscine-drug-information\" class=\"drug drug_general\">scopolamine</a>, <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>, and <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> for prophylaxis. (See <a href=\"#H3330082503\" class=\"local\">'High-risk adults'</a> above.)</p><p/><p class=\"bulletIndent1\">For high-risk children (ie, with history of prior POV, or three to four risk factors), we offer regional anesthesia with sedation to older children if possible, use TIVA with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> for general anesthesia, and administer <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> and <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> for prophylaxis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients at moderate risk of PONV should receive one or two prophylactic interventions. (See <a href=\"#H2609076195\" class=\"local\">'Moderate-risk adults'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For moderate-risk adults (ie, with two or three risk factors), we choose one or two interventions, including either modification of the anesthetic technique (ie, regional anesthesia or TIVA with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a>), administration of an antiemetic, or acupuncture.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For moderate-risk children (ie, those who undergo ear nose and throat, ophthalmologic, or gastrointestinal diagnostic procedures, anesthetics &gt;2 hours long, or require large doses of opioids [ie, <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> &ge;0.2 <span class=\"nowrap\">mg/kg</span> IV or <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a> &ge;5 to 10 <span class=\"nowrap\">mcg/kg</span> IV]), we use the same approach as we would for high-risk children, without using TIVA.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients at low risk of PONV (ie, with zero or one risk factor), prophylaxis for PONV should be based on clinician and patient preference, formulary issues, and cost. It is reasonable to not administer any prophylactic antiemetic and to treat promptly if PONV occurs. (See <a href=\"#H3213524084\" class=\"local\">'Low-risk adults and children'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For low-risk adults who receive inhalation anesthesia or TIVA that includes opioids, we usually administer <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> 4 mg IV at the end of surgery. For low-risk adults who receive TIVA with <a href=\"topic.htm?path=propofol-drug-information\" class=\"drug drug_general\">propofol</a> without opioid, we do not usually administer PONV prophylaxis, though others do.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For low-risk children, we administer <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">ondansetron</a> 0.1 <span class=\"nowrap\">mg/kg</span> IV, maximum 4 mg.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rescue therapy for PONV that occurs in the postanesthesia care unit (PACU) or operating room should include a drug from a different class than those that have already been administered, unless the effect of the first drug has worn off or a potentially inadequate dose has been administered. (See <a href=\"#H2230341374\" class=\"local\">'Rescue therapy'</a> above and <a href=\"#H2659650314\" class=\"local\">'Our strategy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Postdischarge nausea and vomiting (PDNV) may occur in as many as 37 percent of adults who undergo same-day surgery. Risk factors for PDNV include nausea in the PACU and opioids administered in the PACU, in addition to the risk factors for PONV. Prophylaxis may include administration of longer-acting antiemetics (eg, <a href=\"topic.htm?path=aprepitant-drug-information\" class=\"drug drug_general\">aprepitant</a>, <a href=\"topic.htm?path=palonosetron-drug-information\" class=\"drug drug_general\">palonosetron</a>, transdermal <a href=\"topic.htm?path=scopolamine-hyoscine-drug-information\" class=\"drug drug_general\">scopolamine</a>) or repeat, scheduled doses of the shorter-acting antiemetics. (See <a href=\"#H959820332\" class=\"local\">'Postdischarge nausea and vomiting'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/1\" class=\"nounderline abstract_t\">Macario A, Weinger M, Carney S, Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg 1999; 89:652.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/2\" class=\"nounderline abstract_t\">Fortier J, Chung F, Su J. Unanticipated admission after ambulatory surgery--a prospective study. Can J Anaesth 1998; 45:612.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/3\" class=\"nounderline abstract_t\">Hill RP, Lubarsky DA, Phillips-Bute B, et al. Cost-effectiveness of prophylactic antiemetic therapy with ondansetron, droperidol, or placebo. Anesthesiology 2000; 92:958.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/4\" class=\"nounderline abstract_t\">Bashashati M, McCallum RW. Neurochemical mechanisms and pharmacologic strategies in managing nausea and vomiting related to cyclic vomiting syndrome and other gastrointestinal disorders. Eur J Pharmacol 2014; 722:79.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/5\" class=\"nounderline abstract_t\">Becker DE. Nausea, vomiting, and hiccups: a review of mechanisms and treatment. Anesth Prog 2010; 57:150.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/6\" class=\"nounderline abstract_t\">Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil 2007; 19 Suppl 2:25.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/7\" class=\"nounderline abstract_t\">Horn CC, Wallisch WJ, Homanics GE, Williams JP. Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting. Eur J Pharmacol 2014; 722:55.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/8\" class=\"nounderline abstract_t\">Bountra C, Gale JD, Gardner CJ, et al. Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. Oncology 1996; 53 Suppl 1:102.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/9\" class=\"nounderline abstract_t\">Mitchelson F. Pharmacological agents affecting emesis. A review (Part I). Drugs 1992; 43:295.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/10\" class=\"nounderline abstract_t\">Cohen MM, Duncan PG, DeBoer DP, Tweed WA. The postoperative interview: assessing risk factors for nausea and vomiting. Anesth Analg 1994; 78:7.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/11\" class=\"nounderline abstract_t\">Apfel CC, L&auml;&auml;r&auml; E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999; 91:693.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/12\" class=\"nounderline abstract_t\">Koivuranta M, L&auml;&auml;r&auml; E, Sn&aring;re L, Alahuhta S. A survey of postoperative nausea and vomiting. Anaesthesia 1997; 52:443.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/13\" class=\"nounderline abstract_t\">Kranke P, Eberhart LH, Toker H, et al. A prospective evaluation of the POVOC score for the prediction of postoperative vomiting in children. Anesth Analg 2007; 105:1592.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/14\" class=\"nounderline abstract_t\">Apfel CC, Heidrich FM, Jukar-Rao S, et al. Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth 2012; 109:742.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/15\" class=\"nounderline abstract_t\">Sinclair DR, Chung F, Mezei G. Can postoperative nausea and vomiting be predicted? Anesthesiology 1999; 91:109.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/16\" class=\"nounderline abstract_t\">Eberhart LH, Geldner G, Kranke P, et al. The development and validation of a risk score to predict the probability of postoperative vomiting in pediatric patients. Anesth Analg 2004; 99:1630.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/17\" class=\"nounderline abstract_t\">Eberhart LH, Morin AM, Guber D, et al. Applicability of risk scores for postoperative nausea and vomiting in adults to paediatric patients. Br J Anaesth 2004; 93:386.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/18\" class=\"nounderline abstract_t\">Rowley MP, Brown TC. Postoperative vomiting in children. Anaesth Intensive Care 1982; 10:309.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/19\" class=\"nounderline abstract_t\">Palazzo M, Evans R. Logistic regression analysis of fixed patient factors for postoperative sickness: a model for risk assessment. Br J Anaesth 1993; 70:135.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/20\" class=\"nounderline abstract_t\">Stadler M, Bardiau F, Seidel L, et al. Difference in risk factors for postoperative nausea and vomiting. Anesthesiology 2003; 98:46.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/21\" class=\"nounderline abstract_t\">Apfel CC, Philip BK, Cakmakkaya OS, et al. Who is at risk for postdischarge nausea and vomiting after ambulatory surgery? Anesthesiology 2012; 117:475.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/22\" class=\"nounderline abstract_t\">da Silva HB, Sousa AM, Guimar&atilde;es GM, et al. Does previous chemotherapy-induced nausea and vomiting predict postoperative nausea and vomiting? Acta Anaesthesiol Scand 2015; 59:1145.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/23\" class=\"nounderline abstract_t\">Apfel CC, Kranke P, Katz MH, et al. Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: a randomized controlled trial of factorial design. Br J Anaesth 2002; 88:659.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/24\" class=\"nounderline abstract_t\">Fern&aacute;ndez-Guisasola J, G&oacute;mez-Arnau JI, Cabrera Y, del Valle SG. Association between nitrous oxide and the incidence of postoperative nausea and vomiting in adults: a systematic review and meta-analysis. Anaesthesia 2010; 65:379.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/25\" class=\"nounderline abstract_t\">Tram&egrave;r M, Moore A, McQuay H. Omitting nitrous oxide in general anaesthesia: meta-analysis of intraoperative awareness and postoperative emesis in randomized controlled trials. Br J Anaesth 1996; 76:186.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/26\" class=\"nounderline abstract_t\">Sneyd JR, Carr A, Byrom WD, Bilski AJ. A meta-analysis of nausea and vomiting following maintenance of anaesthesia with propofol or inhalational agents. Eur J Anaesthesiol 1998; 15:433.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/27\" class=\"nounderline abstract_t\">St Pierre M, Dunkel M, Rutherford A, Hering W. Does etomidate increase postoperative nausea? A double-blind controlled comparison of etomidate in lipid emulsion with propofol for balanced anaesthesia. Eur J Anaesthesiol 2000; 17:634.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/28\" class=\"nounderline abstract_t\">Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg 2004; 99:482.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/29\" class=\"nounderline abstract_t\">Felts JA, Poler SM, Spitznagel EL. Nitrous oxide, nausea, and vomiting after outpatient gynecologic surgery. J Clin Anesth 1990; 2:168.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/30\" class=\"nounderline abstract_t\">Bloomfield E, Porembka D, Grimes-Rice M. Avoidance of nitrous oxide and increased isoflurane during alfentanil based anesthesia decreases the incidence of postoperative nausea. Anesth Prog 1997; 44:27.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/31\" class=\"nounderline abstract_t\">Vanacker BF. The impact of nitrous oxide on postoperative nausea and vomiting after desflurane anesthesia for breast surgery. Acta Anaesthesiol Belg 1999; 50:77.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/32\" class=\"nounderline abstract_t\">Hovorka J, Korttila K, Erkola O. Nitrous oxide does not increase nausea and vomiting following gynaecological laparoscopy. Can J Anaesth 1989; 36:145.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/33\" class=\"nounderline abstract_t\">Taylor E, Feinstein R, White PF, Soper N. Anesthesia for laparoscopic cholecystectomy. Is nitrous oxide contraindicated? Anesthesiology 1992; 76:541.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/34\" class=\"nounderline abstract_t\">Ichinohe T, Kaneko Y. Nitrous oxide does not aggravate postoperative emesis after orthognathic surgery in female and nonsmoking patients. J Oral Maxillofac Surg 2007; 65:936.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/35\" class=\"nounderline abstract_t\">Apfel CC, Kranke P, Eberhart LH, et al. Comparison of predictive models for postoperative nausea and vomiting. Br J Anaesth 2002; 88:234.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/36\" class=\"nounderline abstract_t\">Wallenborn J, Gelbrich G, Bulst D, et al. Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial. BMJ 2006; 333:324.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/37\" class=\"nounderline abstract_t\">Roberts GW, Bekker TB, Carlsen HH, et al. Postoperative nausea and vomiting are strongly influenced by postoperative opioid use in a dose-related manner. Anesth Analg 2005; 101:1343.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/38\" class=\"nounderline abstract_t\">Cheng CR, Sessler DI, Apfel CC. Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting? Anesth Analg 2005; 101:1349.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/39\" class=\"nounderline abstract_t\">Tram&egrave;r M, Moore A, McQuay H. Prevention of vomiting after paediatric strabismus surgery: a systematic review using the numbers-needed-to-treat method. Br J Anaesth 1995; 75:556.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/40\" class=\"nounderline abstract_t\">Ferrari LR, Donlon JV. Metoclopramide reduces the incidence of vomiting after tonsillectomy in children. Anesth Analg 1992; 75:351.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/41\" class=\"nounderline abstract_t\">Villeret I, Laffon M, Duchalais A, et al. Incidence of postoperative nausea and vomiting in paediatric ambulatory surgery. Paediatr Anaesth 2002; 12:712.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/42\" class=\"nounderline abstract_t\">Apfel CC, Turan A, Souza K, et al. Intravenous acetaminophen reduces postoperative nausea and vomiting: a systematic review and meta-analysis. Pain 2013; 154:677.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/43\" class=\"nounderline abstract_t\">Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2014; 118:85.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/44\" class=\"nounderline abstract_t\">Apfel CC, Meyer A, Orhan-Sungur M, et al. Supplemental intravenous crystalloids for the prevention of postoperative nausea and vomiting: quantitative review. Br J Anaesth 2012; 108:893.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/45\" class=\"nounderline abstract_t\">Goodarzi M, Matar MM, Shafa M, et al. A prospective randomized blinded study of the effect of intravenous fluid therapy on postoperative nausea and vomiting in children undergoing strabismus surgery. Paediatr Anaesth 2006; 16:49.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/46\" class=\"nounderline abstract_t\">Ashok V, Bala I, Bharti N, et al. Effects of intraoperative liberal fluid therapy on postoperative nausea and vomiting in children-A randomized controlled trial. Paediatr Anaesth 2017; 27:810.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/47\" class=\"nounderline abstract_t\">Mishra A, Pandey RK, Sharma A, et al. Is perioperative administration of 5% dextrose effective in reducing the incidence of PONV in laparoscopic cholecystectomy?: A randomized control trial. J Clin Anesth 2017; 40:7.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/48\" class=\"nounderline abstract_t\">Dabu-Bondoc S, Vadivelu N, Shimono C, et al. Intravenous dextrose administration reduces postoperative antiemetic rescue treatment requirements and postanesthesia care unit length of stay. Anesth Analg 2013; 117:591.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/49\" class=\"nounderline abstract_t\">Rao V, Bala I, Jain D, Bharti N. Effect of intravenous dextrose administration on postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: A randomised controlled trial. Eur J Anaesthesiol 2017; 34:705.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/50\" class=\"nounderline abstract_t\">Patel P, Meineke MN, Rasmussen T, et al. The relationship of intravenous dextrose administration during emergence from anesthesia to postoperative nausea and vomiting: a randomized controlled trial. Anesth Analg 2013; 117:34.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/51\" class=\"nounderline abstract_t\">McCaul C, Moran C, O'Cronin D, et al. Intravenous fluid loading with or without supplementary dextrose does not prevent nausea, vomiting and pain after laparoscopy. Can J Anaesth 2003; 50:440.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/52\" class=\"nounderline abstract_t\">Khetarpal R, Chatrath V, Kaur J, et al. Impact of different intravenous fluids on blood glucose levels in nondiabetic patients undergoing elective major noncardiac surgeries. Anesth Essays Res 2016; 10:425.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/53\" class=\"nounderline abstract_t\">Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004; 350:2441.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/54\" class=\"nounderline abstract_t\">Tram&egrave;r MR, Reynolds DJ, Moore RA, McQuay HJ. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. Anesthesiology 1997; 87:1277.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/55\" class=\"nounderline abstract_t\">Davis PJ, Fertal KM, Boretsky KR, et al. The effects of oral ondansetron disintegrating tablets for prevention of at-home emesis in pediatric patients after ear-nose-throat surgery. Anesth Analg 2008; 106:1117.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/56\" class=\"nounderline abstract_t\">Cohen IT, Joffe D, Hummer K, Soluri A. Ondansetron oral disintegrating tablets: acceptability and efficacy in children undergoing adenotonsillectomy. Anesth Analg 2005; 101:59.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/57\" class=\"nounderline abstract_t\">Zarate E, Watcha MF, White PF, et al. A comparison of the costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis. Anesth Analg 2000; 90:1352.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/58\" class=\"nounderline abstract_t\">Honkavaara P. Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia. Br J Anaesth 1996; 76:316.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/59\" class=\"nounderline abstract_t\">Dershwitz M, Conant JA, Chang Y, et al. A randomized, double-blind, dose-response study of ondansetron in the prevention of postoperative nausea and vomiting. J Clin Anesth 1998; 10:314.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/60\" class=\"nounderline abstract_t\">Khalil SN, Roth AG, Cohen IT, et al. A double-blind comparison of intravenous ondansetron and placebo for preventing postoperative emesis in 1- to 24-month-old pediatric patients after surgery under general anesthesia. Anesth Analg 2005; 101:356.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/61\" class=\"nounderline abstract_t\">Wilson AJ, Diemunsch P, Lindeque BG, et al. Single-dose i.v. granisetron in the prevention of postoperative nausea and vomiting. Br J Anaesth 1996; 76:515.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/62\" class=\"nounderline abstract_t\">Cieslak GD, Watcha MF, Phillips MB, Pennant JH. The dose-response relation and cost-effectiveness of granisetron for the prophylaxis of pediatric postoperative emesis. Anesthesiology 1996; 85:1076.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/63\" class=\"nounderline abstract_t\">Philip BK, McLeskey CH, Chelly JE, et al. Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. The Dolasetron Prophylaxis Study Group. J Clin Anesth 2000; 12:1.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/64\" class=\"nounderline abstract_t\">Rojas C, Stathis M, Thomas AG, et al. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 2008; 107:469.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/65\" class=\"nounderline abstract_t\">Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 2010; 626:193.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/66\" class=\"nounderline abstract_t\">Kovac AL, Eberhart L, Kotarski J, et al. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesth Analg 2008; 107:439.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/67\" class=\"nounderline abstract_t\">Candiotti KA, Kovac AL, Melson TI, et al. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting. Anesth Analg 2008; 107:445.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/68\" class=\"nounderline abstract_t\">Wang JJ, Ho ST, Lee SC, et al. The use of dexamethasone for preventing postoperative nausea and vomiting in females undergoing thyroidectomy: a dose-ranging study. Anesth Analg 2000; 91:1404.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/69\" class=\"nounderline abstract_t\">Henzi I, Walder B, Tram&egrave;r MR. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg 2000; 90:186.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/70\" class=\"nounderline abstract_t\">Weren M, Demeere JL. Methylprednisolone vs. dexamethasone in the prevention of postoperative nausea and vomiting: a prospective, randomised, double-blind, placebo-controlled trial. Acta Anaesthesiol Belg 2008; 59:1.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/71\" class=\"nounderline abstract_t\">De Oliveira GS Jr, Castro-Alves LJ, Ahmad S, et al. Dexamethasone to prevent postoperative nausea and vomiting: an updated meta-analysis of randomized controlled trials. Anesth Analg 2013; 116:58.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/72\" class=\"nounderline abstract_t\">De Oliveira GS Jr, Almeida MD, Benzon HT, McCarthy RJ. Perioperative single dose systemic dexamethasone for postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology 2011; 115:575.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/73\" class=\"nounderline abstract_t\">Lunn TH, Kehlet H. Perioperative glucocorticoids in hip and knee surgery - benefit vs. harm? A review of randomized clinical trials. Acta Anaesthesiol Scand 2013; 57:823.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/74\" class=\"nounderline abstract_t\">Bolac CS, Wallace AH, Broadwater G, et al. The impact of postoperative nausea and vomiting prophylaxis with dexamethasone on postoperative wound complications in patients undergoing laparotomy for endometrial cancer. Anesth Analg 2013; 116:1041.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/75\" class=\"nounderline abstract_t\">Kurz A, Fleischmann E, Sessler DI, et al. Effects of supplemental oxygen and dexamethasone on surgical site infection: a factorial randomized trial&Dagger;. Br J Anaesth 2015; 115:434.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/76\" class=\"nounderline abstract_t\">Corcoran T, Kasza J, Short TG, et al. Intraoperative dexamethasone does not increase the risk of postoperative wound infection: a propensity score-matched post hoc analysis of the ENIGMA-II trial (EnDEX). Br J Anaesth 2017; 118:190.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/77\" class=\"nounderline abstract_t\">Toner AJ, Ganeshanathan V, Chan MT, et al. Safety of Perioperative Glucocorticoids in Elective Noncardiac Surgery: A Systematic Review and Meta-analysis. Anesthesiology 2017; 126:234.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/78\" class=\"nounderline abstract_t\">Nazar CE, Lacassie HJ, L&oacute;pez RA, Mu&ntilde;oz HR. Dexamethasone for postoperative nausea and vomiting prophylaxis: effect on glycaemia in obese patients with impaired glucose tolerance. Eur J Anaesthesiol 2009; 26:318.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/79\" class=\"nounderline abstract_t\">Hans P, Vanthuyne A, Dewandre PY, et al. Blood glucose concentration profile after 10 mg dexamethasone in non-diabetic and type 2 diabetic patients undergoing abdominal surgery. Br J Anaesth 2006; 97:164.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/80\" class=\"nounderline abstract_t\">Tien M, Gan TJ, Dhakal I, et al. The effect of anti-emetic doses of dexamethasone on postoperative blood glucose levels in non-diabetic and diabetic patients: a prospective randomised controlled study. Anaesthesia 2016; 71:1037.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/81\" class=\"nounderline abstract_t\">Madan R, Bhatia A, Chakithandy S, et al. Prophylactic dexamethasone for postoperative nausea and vomiting in pediatric strabismus surgery: a dose ranging and safety evaluation study. Anesth Analg 2005; 100:1622.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/82\" class=\"nounderline abstract_t\">White PF, Tang J, Song D, et al. Transdermal scopolamine: an alternative to ondansetron and droperidol for the prevention of postoperative and postdischarge emetic symptoms. Anesth Analg 2007; 104:92.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/83\" class=\"nounderline abstract_t\">Apfel CC, Zhang K, George E, et al. Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis. Clin Ther 2010; 32:1987.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/84\" class=\"nounderline abstract_t\">Kranke P, Morin AM, Roewer N, et al. The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg 2002; 95:133.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/85\" class=\"nounderline abstract_t\">Seo SW, Suh MK, Chin J, Na DL. Mental confusion associated with scopolamine patch in elderly with mild cognitive impairment (MCI). Arch Gerontol Geriatr 2009; 49:204.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/86\" class=\"nounderline abstract_t\">Sah N, Ramesh V, Kaul B, et al. Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery. J Clin Anesth 2009; 21:249.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/87\" class=\"nounderline abstract_t\">Domino KB, Anderson EA, Polissar NL, Posner KL. Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis. Anesth Analg 1999; 88:1370.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/88\" class=\"nounderline abstract_t\">Fortney JT, Gan TJ, Graczyk S, et al. A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups. Anesth Analg 1998; 86:731.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/89\" class=\"nounderline abstract_t\">Charbit B, Albaladejo P, Funck-Brentano C, et al. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005; 102:1094.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/90\" class=\"nounderline abstract_t\">Chan MT, Choi KC, Gin T, et al. The additive interactions between ondansetron and droperidol for preventing postoperative nausea and vomiting. Anesth Analg 2006; 103:1155.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/91\" class=\"nounderline abstract_t\">Weissenburger J, Funck-Brentano C, Jaillon P, Charbit B. Droperidol and ondansetron in vitro electrophysiological drug interaction study. Fundam Clin Pharmacol 2009; 23:719.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/92\" class=\"nounderline abstract_t\">Feng PH, Chu KS, Lu IC, et al. Haloperidol plus ondansetron prevents postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy. Acta Anaesthesiol Taiwan 2009; 47:3.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/93\" class=\"nounderline abstract_t\">Diemunsch P, Gan TJ, Philip BK, et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. Br J Anaesth 2007; 99:202.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/94\" class=\"nounderline abstract_t\">Gan TJ, Apfel CC, Kovac A, et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg 2007; 104:1082.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/95\" class=\"nounderline abstract_t\">Habib AS, Keifer JC, Borel CO, et al. A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy. Anesth Analg 2011; 112:813.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/96\" class=\"nounderline abstract_t\">Gan TJ, Gu J, Singla N, et al. Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial. Anesth Analg 2011; 112:804.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/97\" class=\"nounderline abstract_t\">Kranke P, Morin AM, Roewer N, Eberhart LH. Dimenhydrinate for prophylaxis of postoperative nausea and vomiting: a meta-analysis of randomized controlled trials. Acta Anaesthesiol Scand 2002; 46:238.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/98\" class=\"nounderline abstract_t\">Schnabel A, Eberhart LH, Muellenbach R, et al. Efficacy of perphenazine to prevent postoperative nausea and vomiting: a quantitative systematic review. Eur J Anaesthesiol 2010; 27:1044.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/99\" class=\"nounderline abstract_t\">Khalil S, Philbrook L, Rabb M, et al. Ondansetron/promethazine combination or promethazine alone reduces nausea and vomiting after middle ear surgery. J Clin Anesth 1999; 11:596.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/100\" class=\"nounderline abstract_t\">Chia YY, Lo Y, Liu K, et al. The effect of promethazine on postoperative pain: a comparison of preoperative, postoperative, and placebo administration in patients following total abdominal hysterectomy. Acta Anaesthesiol Scand 2004; 48:625.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/101\" class=\"nounderline abstract_t\">Chen JJ, Frame DG, White TJ. Efficacy of ondansetron and prochlorperazine for the prevention of postoperative nausea and vomiting after total hip replacement or total knee replacement procedures: a randomized, double-blind, comparative trial. Arch Intern Med 1998; 158:2124.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/102\" class=\"nounderline abstract_t\">Tram&egrave;r M, Moore A, McQuay H. Meta-analytic comparison of prophylactic antiemetic efficacy for postoperative nausea and vomiting: propofol anaesthesia vs omitting nitrous oxide vs total i.v. anaesthesia with propofol. Br J Anaesth 1997; 78:256.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/103\" class=\"nounderline abstract_t\">Visser K, Hassink EA, Bonsel GJ, et al. Randomized controlled trial of total intravenous anesthesia with propofol versus inhalation anesthesia with isoflurane-nitrous oxide: postoperative nausea with vomiting and economic analysis. Anesthesiology 2001; 95:616.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/104\" class=\"nounderline abstract_t\">Tram&egrave;r M, Moore A, McQuay H. Propofol anaesthesia and postoperative nausea and vomiting: quantitative systematic review of randomized controlled studies. Br J Anaesth 1997; 78:247.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/105\" class=\"nounderline abstract_t\">Deutschman CS, Traber KB. Evolution of anesthesiology. Anesthesiology 1996; 85:1.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/106\" class=\"nounderline abstract_t\">Gan TJ, Glass PS, Howell ST, et al. Determination of plasma concentrations of propofol associated with 50% reduction in postoperative nausea. Anesthesiology 1997; 87:779.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/107\" class=\"nounderline abstract_t\">Erdem AF, Yoruk O, Alici HA, et al. Subhypnotic propofol infusion plus dexamethasone is more effective than dexamethasone alone for the prevention of vomiting in children after tonsillectomy. Paediatr Anaesth 2008; 18:878.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/108\" class=\"nounderline abstract_t\">Kranke P. Putting the record straight: granisetron's efficacy as an antiemetic 'post-Fujii'. Anaesthesia 2012; 67:1063.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/109\" class=\"nounderline abstract_t\">De Oliveira GS Jr, Castro-Alves LJ, Chang R, et al. Systemic metoclopramide to prevent postoperative nausea and vomiting: a meta-analysis without Fujii's studies. Br J Anaesth 2012; 109:688.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/110\" class=\"nounderline abstract_t\">Yis U, Ozdemir D, Duman M, Unal N. Metoclopramide induced dystonia in children: two case reports. Eur J Emerg Med 2005; 12:117.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/111\" class=\"nounderline abstract_t\">Grant MC, Kim J, Page AJ, et al. The Effect of Intravenous Midazolam on Postoperative Nausea and Vomiting: A Meta-Analysis. Anesth Analg 2016; 122:656.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/112\" class=\"nounderline abstract_t\">Ahn EJ, Kang H, Choi GJ, et al. The Effectiveness of Midazolam for Preventing Postoperative Nausea and Vomiting: A Systematic Review and Meta-Analysis. Anesth Analg 2016; 122:664.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/113\" class=\"nounderline abstract_t\">Arslan M, Ci&ccedil;ek R, Kalender H&Uuml;, Yilmaz H. Preventing postoperative nausea and vomiting after laparoscopic cholecystectomy: a prospective, randomized, double-blind study. Curr Ther Res Clin Exp 2011; 72:1.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/114\" class=\"nounderline abstract_t\">Gan TJ, Sinha AC, Kovac AL, et al. A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron alone for the prevention of postoperative nausea and vomiting in the outpatient setting. Anesth Analg 2009; 108:1498.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/115\" class=\"nounderline abstract_t\">Habib AS, El-Moalem HE, Gan TJ. The efficacy of the 5-HT3 receptor antagonists combined with droperidol for PONV prophylaxis is similar to their combination with dexamethasone. A meta-analysis of randomized controlled trials. Can J Anaesth 2004; 51:311.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/116\" class=\"nounderline abstract_t\">Eberhart LH, Morin AM, Bothner U, Georgieff M. Droperidol and 5-HT3-receptor antagonists, alone or in combination, for prophylaxis of postoperative nausea and vomiting. A meta-analysis of randomised controlled trials. Acta Anaesthesiol Scand 2000; 44:1252.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/117\" class=\"nounderline abstract_t\">Splinter WM, Rhine EJ. Low-dose ondansetron with dexamethasone more effectively decreases vomiting after strabismus surgery in children than does high-dose ondansetron. Anesthesiology 1998; 88:72.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/118\" class=\"nounderline abstract_t\">Shende D, Bharti N, Kathirvel S, Madan R. Combination of droperidol and ondansetron reduces PONV after pediatric strabismus surgery more than single drug therapy. Acta Anaesthesiol Scand 2001; 45:756.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/119\" class=\"nounderline abstract_t\">Holt R, Rask P, Coulthard KP, et al. Tropisetron plus dexamethasone is more effective than tropisetron alone for the prevention of postoperative nausea and vomiting in children undergoing tonsillectomy. Paediatr Anaesth 2000; 10:181.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/120\" class=\"nounderline abstract_t\">Som A, Bhattacharjee S, Maitra S, et al. Combination of 5-HT3 Antagonist and Dexamethasone Is Superior to 5-HT3 Antagonist Alone for PONV Prophylaxis After Laparoscopic Surgeries: A Meta-analysis. Anesth Analg 2016; 123:1418.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/121\" class=\"nounderline abstract_t\">Splinter WM. Prevention of vomiting after strabismus surgery in children: dexamethasone alone versus dexamethasone plus low-dose ondansetron. Paediatr Anaesth 2001; 11:591.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/122\" class=\"nounderline abstract_t\">Lee A, Chan SK, Fan LT. Stimulation of the wrist acupuncture point PC6 for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev 2015; :CD003281.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/123\" class=\"nounderline abstract_t\">Dune LS, Shiao SY. Metaanalysis of acustimulation effects on postoperative nausea and vomiting in children. Explore (NY) 2006; 2:314.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/124\" class=\"nounderline abstract_t\">Hines S, Steels E, Chang A, Gibbons K. Aromatherapy for treatment of postoperative nausea and vomiting. Cochrane Database Syst Rev 2012; :CD007598.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/125\" class=\"nounderline abstract_t\">Maxwell LG, Kaufmann SC, Bitzer S, et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. Anesth Analg 2005; 100:953.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/126\" class=\"nounderline abstract_t\">Mattila K, Toivonen J, Janhunen L, et al. Postdischarge symptoms after ambulatory surgery: first-week incidence, intensity, and risk factors. Anesth Analg 2005; 101:1643.</a></li><li><a href=\"https://www.uptodate.com/contents/postoperative-nausea-and-vomiting/abstract/127\" class=\"nounderline abstract_t\">Pan PH, Lee SC, Harris LC. Antiemetic prophylaxis for postdischarge nausea and vomiting and impact on functional quality of living during recovery in patients with high emetic risks: a prospective, randomized, double-blind comparison of two prophylactic antiemetic regimens. Anesth Analg 2008; 107:429.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 16849 Version 20.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H959820338\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H959820015\" id=\"outline-link-H959820015\">INTRODUCTION</a></li><li><a href=\"#H2239430484\" id=\"outline-link-H2239430484\">PATHOPHYSIOLOGY</a></li><li><a href=\"#H712007825\" id=\"outline-link-H712007825\">RISK FACTORS</a><ul><li><a href=\"#H3592868051\" id=\"outline-link-H3592868051\">Patient risk factors</a></li><li><a href=\"#H2162413264\" id=\"outline-link-H2162413264\">Anesthetic factors</a></li><li><a href=\"#H2012868701\" id=\"outline-link-H2012868701\">Type of surgery</a></li><li><a href=\"#H435405590\" id=\"outline-link-H435405590\">Risk scores</a><ul><li><a href=\"#H440882333\" id=\"outline-link-H440882333\">- Risk score for postoperative nausea and vomiting for adults</a></li><li><a href=\"#H2088878686\" id=\"outline-link-H2088878686\">- Risk score for postoperative vomiting for children</a></li></ul></li></ul></li><li><a href=\"#H1226576483\" id=\"outline-link-H1226576483\">PREVENTION</a><ul><li><a href=\"#H2659650314\" id=\"outline-link-H2659650314\">Our strategy</a><ul><li><a href=\"#H620505717\" id=\"outline-link-H620505717\">- Preventive measures for all patients</a></li><li><a href=\"#H1157266081\" id=\"outline-link-H1157266081\">- Risk stratification</a></li><li><a href=\"#H3330082503\" id=\"outline-link-H3330082503\">- High-risk adults</a></li><li><a href=\"#H1924075264\" id=\"outline-link-H1924075264\">- High-risk children</a></li><li><a href=\"#H2609076195\" id=\"outline-link-H2609076195\">- Moderate-risk adults</a></li><li><a href=\"#H495765039\" id=\"outline-link-H495765039\">- Moderate-risk children</a></li><li><a href=\"#H3213524084\" id=\"outline-link-H3213524084\">- Low-risk adults and children</a></li></ul></li><li><a href=\"#H2892527150\" id=\"outline-link-H2892527150\">Interventions for prophylaxis</a><ul><li><a href=\"#H1499538518\" id=\"outline-link-H1499538518\">- Reduction of baseline risk</a></li><li><a href=\"#H144014180\" id=\"outline-link-H144014180\">- Antiemetics</a><ul><li><a href=\"#H2430614242\" id=\"outline-link-H2430614242\">General principles</a></li><li><a href=\"#H3622478147\" id=\"outline-link-H3622478147\">Serotonin (5-hydroxytryptamine) receptor antagonists</a></li><li><a href=\"#H72946217\" id=\"outline-link-H72946217\">Glucocorticoids</a></li><li><a href=\"#H316232496\" id=\"outline-link-H316232496\">Anticholinergics</a></li><li><a href=\"#H2984798969\" id=\"outline-link-H2984798969\">Butyrophenones</a></li><li><a href=\"#H766421411\" id=\"outline-link-H766421411\">Neurokinin 1 receptor antagonists</a></li><li><a href=\"#H3187996832\" id=\"outline-link-H3187996832\">Antihistamines</a></li><li><a href=\"#H978039586\" id=\"outline-link-H978039586\">Phenothiazines</a></li><li><a href=\"#H4207421783\" id=\"outline-link-H4207421783\">Propofol</a></li><li><a href=\"#H3571900129\" id=\"outline-link-H3571900129\">Metoclopramide</a></li><li><a href=\"#H4194392610\" id=\"outline-link-H4194392610\">Midazolam</a></li></ul></li><li><a href=\"#H2447268839\" id=\"outline-link-H2447268839\">- Combination therapy</a></li><li><a href=\"#H959820222\" id=\"outline-link-H959820222\">- Nonpharmacologic techniques</a><ul><li><a href=\"#H695815149\" id=\"outline-link-H695815149\">Acupuncture</a></li><li><a href=\"#H959820240\" id=\"outline-link-H959820240\">Isopropyl alcohol</a></li></ul></li></ul></li></ul></li><li><a href=\"#H2230341374\" id=\"outline-link-H2230341374\">RESCUE THERAPY</a></li><li><a href=\"#H959820332\" id=\"outline-link-H959820332\">POSTDISCHARGE NAUSEA AND VOMITING</a></li><li><a href=\"#H2737199774\" id=\"outline-link-H2737199774\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H554591314\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H959820338\" id=\"outline-link-H959820338\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ANEST/16849|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=ANEST/111057\" class=\"graphic graphic_algorithm\">- Prophylaxis for PONV in adults</a></li></ul></li><li><div id=\"ANEST/16849|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ANEST/110527\" class=\"graphic graphic_figure\">- Pathophysiologic pathways for postoperative nausea and vomiting</a></li><li><a href=\"image.htm?imageKey=ANEST/86808\" class=\"graphic graphic_figure\">- Simplified risk scores for POV/PONV</a></li><li><a href=\"image.htm?imageKey=ANEST/107494\" class=\"graphic graphic_figure\">- Simplified risk score for PDNV in adults</a></li></ul></li><li><div id=\"ANEST/16849|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ANEST/107138\" class=\"graphic graphic_picture\">- Location of P6 acupoint</a></li></ul></li><li><div id=\"ANEST/16849|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=SURG/65891\" class=\"graphic graphic_table\">- Anti-emetic agents for postoperative nausea and vomiting</a></li><li><a href=\"image.htm?imageKey=CARD/57431\" class=\"graphic graphic_table\">- Causes of long QT syndrome</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=anesthesia-for-tonsillectomy-with-or-without-adenoidectomy-in-children\" class=\"medical medical_review\">Anesthesia for tonsillectomy with or without adenoidectomy in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-with-nausea-and-vomiting\" class=\"medical medical_review\">Approach to the adult with nausea and vomiting</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=characteristics-of-antiemetic-drugs\" class=\"medical medical_review\">Characteristics of antiemetic drugs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=emergence-delirium-and-agitation-in-children\" class=\"medical medical_review\">Emergence delirium and agitation in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intraoperative-fluid-management\" class=\"medical medical_review\">Intraoperative fluid management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-acute-perioperative-pain\" class=\"medical medical_review\">Management of acute perioperative pain</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=metoclopramide-pediatric-drug-information\" class=\"drug drug_pediatric\">Metoclopramide: Pediatric drug information</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathophysiology-and-prediction-of-chemotherapy-induced-nausea-and-vomiting\" class=\"medical medical_review\">Pathophysiology and prediction of chemotherapy-induced nausea and vomiting</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nausea-and-vomiting-after-surgery-the-basics\" class=\"medical medical_basics\">Patient education: Nausea and vomiting after surgery (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-postoperative-nausea-and-vomiting\" class=\"medical medical_society_guidelines\">Society guideline links: Postoperative nausea and vomiting</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tumor-lysis-syndrome-definition-pathogenesis-clinical-manifestations-etiology-and-risk-factors\" class=\"medical medical_review\">Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors</a></li></ul></div></div>","javascript":null}